PharmaCyte Biotech, Inc.
PMCB
$1.04
$0.032.97%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -135.69% | 772.47% | -391.57% | -152.68% | 835.76% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 130.61% | -695.09% | 589.01% | 120.48% | -926.09% |
| Change in Net Operating Assets | -859.59% | 1,344.09% | 211.13% | 18.99% | -80.07% |
| Cash from Operations | -434.15% | -212.43% | -187.92% | 46.85% | -208.83% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 85.40% | 43.85% | -750.61% | 97.19% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | 100.00% | 43.95% | -591.67% | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 98.40% | 43.95% | -1,534.54% | -261.99% |
| Foreign Exchange rate Adjustments | -50.00% | 250.00% | -209.09% | 106.25% | -60.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.64% | 89.02% | 63.52% | -853.29% | -364.92% |